| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, ISO 9001, USP |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Indole-3-carbinol |
| CAS No | 700-06-1 |
| Appearance | Off-White Powder |
| Flash Point | 171.9ºC |
| Specification | 99% |
Indole 3 carbinol (C9H9NO) is produced by the breakdown of the glucosinolate glucobrassicin, which can be found at relatively high levels in cruciferous vegetables such as broccoli, cabbage, cauliflower, brussels sprouts, collard greens and kale. indole-3-carbinol is also available in a dietary supplement. indole-3-carbinol is the subject of on-going Biomedical research into its possible anticarcinogenic, antioxidant, and antiatherogenic effects.
Indole-3-carbinol can shift estrogen metabolism towards less estrogenic metabolites. indole-3-carbinol has an effect on human papilloma virus infected cells in both pediatrics and adult patients.
1. Indole-3-carbinol prevention and treatment of cancer;
2. Indole-3-carbinol may have an effect on human papillomavirus infected cells in both pediatrics and adult patients;
3. Indole-3-carbinol can anti-oxidant;
4. Indole-3-carbinol anticarcinogenic;
5. Indole-3-carbinol anti-atherogenic.
The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants.
Pseudobulbar affect and other neuropsychiatric disorders
In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect (emotional lability). The combination is also under investigation for the treatment of a variety of other neurological and neuropsychiatric conditions, such as agitation associated with Alzheimer's disease andmajor depressive disorder.Dextromethorphan is the actual therapeutic agent in the combination; quinidinemerely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6.
Certificate of Analysis
| Batch Number | Z20190412001 | ||
| Production Date | 2019.04.12 | ||
| Batch Quantity | 80 KGS | ||
| Item | Test Standard | Testing Result | |
| Appearance | Powder | Complies | |
| Color | Off-White fine Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual acetone | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
| Conclusion: Conform with USP Standard | |||
Storage:Closed container. dry & cool. keep away from moisture &strong light
Shelf life:24 Months
Shipping Options as follows
| EMS | Around 7-10 working days |
| DHL | Around 3-5 working days |
| Fedex | Around 4-6 working days |
| TNT | Around 6-7 working days |
| By Air | Around 5-7 working days |
| By Sea | Around 15-30 working days |
Perfect After-Sales Service
FAQ
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}